Please use this identifier to cite or link to this item: http://ahro.austin.org.au/austinjspui/handle/1/10045
Title: A phase 1 and pharmacokinetic study of gemcitabine and oxaliplatin in patients with solid tumors.
Authors: Gan, Hui K;Mitchell, Paul L R;Galettis, Peter;Davis, Ian D;Cebon, Jonathan S;de Souza, Paul;Links, Matthew
Affiliation: Department of Medical Oncology and Ludwig Institute for Cancer Research, Austin Hospital, Heidelberg, Melbourne, VIC, Australia. huikg@bigpond.net.au
Issue Date: 19-Nov-2005
Citation: Cancer Chemotherapy and Pharmacology 2005; 58(2): 157-64
Abstract: This dose escalation study aimed to determine the recommended doses, toxicity and pharmacokinetics of oxaliplatin and gemcitabine given on days 1 and 8 every 21 days. This schedule may maximize dose intensity of both drugs with acceptable or reduced toxicity.Eligible patients had solid malignancies, no more than two prior courses of chemotherapy, ECOG performance status 0-2, neurotoxicity < or = NCI-CTC grade 1 and adequate organ function. Dose escalation commenced at oxaliplatin 40 mg/m(2) and gemcitabine 750 mg/m(2), both given on days 1 and 8 every 21 days, and reached oxaliplatin 80 mg/m(2) and gemcitabine 1,500 mg/m(2). The two highest dose levels were each expanded to six patients to gain additional toxicity data.There were no dose limiting toxicities related to treatment and an MTD was not reached. Five patients (24%) had grade 3 neutropenia, without associated infection, and seven patients (33%) had grade 3/4 thrombocytopenia. Neurotoxicity was mild and no worse than grade 1. Two patients with mesothelioma (10%) had partial responses and 11 patients (52%) had disease stabilization. No pharmacokinetic interaction between oxaliplatin and gemcitabine was detected. Dose intensity was maximal at level 4 (oxaliplatin 70 mg/m(2) and gemcitabine 1,250 mg/m(2)).This schedule allows oxaliplatin and gemcitabine to be delivered at the full dose intensity of each drug with excellent tolerability and predictable pharmacokinetics. The recommended doses for phase II studies are oxaliplatin 70 mg/m(2) and gemcitabine 1,250 mg/m(2) on days 1 and 8 every 21 days.
Internal ID Number: 16328413
URI: http://ahro.austin.org.au/austinjspui/handle/1/10045
DOI: 10.1007/s00280-005-0152-y
URL: http://www.ncbi.nlm.nih.gov/pubmed/16328413
Type: Journal Article
Subjects: Adult
Aged
Antineoplastic Combined Chemotherapy Protocols.adverse effects.pharmacokinetics.therapeutic use
Area Under Curve
Deoxycytidine.administration & dosage.analogs & derivatives
Female
Humans
Male
Middle Aged
Neoplasms.drug therapy.metabolism
Organoplatinum Compounds.administration & dosage
Appears in Collections:Journal articles

Files in This Item:
File SizeFormat 
16328413.pdf60.12 kBAdobe PDFView/Open


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.